glp-1 for nash RAs gain popularity as cure obesity, get explored for NASH, CVDs glp 1 agonist nash The
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 169.Wadden T.A., Bailey T.S., Billings L.K., Davies M., Frias J.P., Koroleva A., Lingvay I., O'Neil P.M., Rubino D.M., Skovgaard D., et al

By improving glycemic control, promoting weight loss, and potentially reducing cardiovascular risk, GLP-1 therapy may indirectly support cognitive health through optimization of metabolic and vascular parameters

Obesity is multi-factorial

So its hardly surprising to see that sales for GLP-1 drugs have leapt by nearly 500% just since 2018: The end of the beginning

This is expected

The link between cognition and somatic conditions related to insulin resistance in the UK biobank study cohort: a systematic review